Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Encouraging study results have shown that Ventaira Pharmaceuticals' new technology delivers medicated aerosol to the lung in higher proportions than ever reported for a hand-held device.
Subscribe to our email newsletter
The specialty pharmaceutical firm has successfully completed a pharmacokinetics and scintigraphy study with fluticasone propionate, a commonly prescribed inhaled steroid treatment for asthma, in combination with Ventaira's next-generation inhalation device.
Complete study results are being prepared for submission to a peer-reviewed journal later this year. The study, conducted by Pharmaceutical Profiles, analyzed the distribution of inhaled fluticasone from the mouth to the lung periphery. The appearance and bioavailability of fluticasone in blood were also analyzed.
Fluticasone was administered by oral inhalation either as a pMDI HFA suspension through an AeroChamber Plus spacer, or by the Ventaira Phoenix device, which is based on Ventaira's Mystic electrohydrodynamic (EHD) technology.
“We are pleased with the results of this study, and we see them as validation of our technology as well as validation of our ability to compete amongst major players in the inhalation space,” stated Leslie Williams, president and CEO of Ventaira. “In addition, these study results will be used to select the formulation and doses for our phase II study that is slated to begin later this year.”